Amarin Corp Plc (AMRN)

[eightisenough]

In a note Friday, Cantor Fitzgerald analyst Louise Chen wrote she was " still positive" on Amarin , despite the FDA approval of the Hikma generic. She said it seemed unlikely that Hikma would begin selling its generic before a decision on the appeal, and thinks Amarin will win its appeal. She also noted the Vascepa supply chain is complicated, and said it could be hard for Hikma to manufacture a large amount of the drug.

Chen rates Amarin Overweight, with a price target of $35 . The stock closed Thursday at $7.28 , and was trading at $6.62 before the market opened on Friday. Of the dozen analysts tracked by FactSet who cover the stock, eight rate it Buy. The average price target is $17.64 . The stock trades at 64.7 times earnings expected over the next 12 months.